226 related articles for article (PubMed ID: 32479501)
21. Decreased bone formation and osteopenia in lamin a/c-deficient mice.
Li W; Yeo LS; Vidal C; McCorquodale T; Herrmann M; Fatkin D; Duque G
PLoS One; 2011 Apr; 6(4):e19313. PubMed ID: 21547077
[TBL] [Abstract][Full Text] [Related]
22. Kynurenine inhibits autophagy and promotes senescence in aged bone marrow mesenchymal stem cells through the aryl hydrocarbon receptor pathway.
Kondrikov D; Elmansi A; Bragg RT; Mobley T; Barrett T; Eisa N; Kondrikova G; Schoeinlein P; Aguilar-Perez A; Shi XM; Fulzele S; Lawrence MM; Hamrick M; Isales C; Hill W
Exp Gerontol; 2020 Feb; 130():110805. PubMed ID: 31812582
[TBL] [Abstract][Full Text] [Related]
23. Tea polysaccharide inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells and ameliorates ovariectomy-induced osteoporosis in rats.
Xu H; Yin D; Liu T; Chen F; Chen Y; Wang X; Sheng J
Biomed Pharmacother; 2018 Jun; 102():539-548. PubMed ID: 29587240
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
25. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
26. DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.
Zhang B; Yuan P; Xu G; Chen Z; Li Z; Ye H; Wang J; Shi P; Sun X
Cell Death Dis; 2021 Sep; 12(9):825. PubMed ID: 34475393
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis.
Rauner M; Sipos W; Goettsch C; Wutzl A; Foisner R; Pietschmann P; Hofbauer LC
J Bone Miner Res; 2009 Jan; 24(1):78-86. PubMed ID: 18767923
[TBL] [Abstract][Full Text] [Related]
28. Identification of Fibroblast Activation Protein as an Osteogenic Suppressor and Anti-osteoporosis Drug Target.
Wei H; Xu Y; Wang Y; Xu L; Mo C; Li L; Shen B; Sun Y; Cheng P; Yang L; Pang Y; Qin A; Cao Y; Morrison SJ; Yue R
Cell Rep; 2020 Oct; 33(2):108252. PubMed ID: 33053358
[TBL] [Abstract][Full Text] [Related]
29. Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo.
Hwang YH; Kim KJ; Kim SJ; Mun SK; Hong SG; Son YJ; Yee ST
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562730
[TBL] [Abstract][Full Text] [Related]
30. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age.
Kim HN; Chang J; Shao L; Han L; Iyer S; Manolagas SC; O'Brien CA; Jilka RL; Zhou D; Almeida M
Aging Cell; 2017 Aug; 16(4):693-703. PubMed ID: 28401730
[TBL] [Abstract][Full Text] [Related]
31. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss.
Collins FL; Williams JO; Bloom AC; Singh RK; Jordan L; Stone MD; McCabe LR; Wang ECY; Williams AS
Bone; 2017 Apr; 97():94-104. PubMed ID: 28062298
[TBL] [Abstract][Full Text] [Related]
32. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
33. IDH2 deficiency increases bone mass with reduced osteoclastogenesis by limiting RANKL expression in osteoblasts.
Lee SH; Lee SH; Lee JH; Park JW; Kim JE
Bone; 2019 Dec; 129():115056. PubMed ID: 31479775
[TBL] [Abstract][Full Text] [Related]
34. Osteocytes regulate senescence of bone and bone marrow.
Ding P; Gao C; Gao Y; Liu D; Li H; Xu J; Chen X; Huang Y; Zhang C; Zheng M; Gao J
Elife; 2022 Oct; 11():. PubMed ID: 36305580
[TBL] [Abstract][Full Text] [Related]
35. Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide -induced osteoporosis by inhibiting osteoclast formation.
Wang XF; Wang YJ; Li TY; Guo JX; Lv F; Li CL; Ge XT
Biomed Pharmacother; 2019 Jul; 115():108916. PubMed ID: 31054506
[TBL] [Abstract][Full Text] [Related]
36. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol counteracts bone loss via mitofilin-mediated osteogenic improvement of mesenchymal stem cells in senescence-accelerated mice.
Lv YJ; Yang Y; Sui BD; Hu CH; Zhao P; Liao L; Chen J; Zhang LQ; Yang TT; Zhang SF; Jin Y
Theranostics; 2018; 8(9):2387-2406. PubMed ID: 29721087
[No Abstract] [Full Text] [Related]
38. AIMP3 induces laminopathy and senescence of vascular smooth muscle cells by reducing lamin A expression and leads to vascular aging in vivo.
Hwang BH; Kim E; Park EH; Kim CW; Lee KY; Kim JJ; Choo EH; Lim S; Choi IJ; Kim CJ; Ihm SH; Chang K
Exp Gerontol; 2021 Oct; 153():111483. PubMed ID: 34274427
[TBL] [Abstract][Full Text] [Related]
39. C/EBPα regulates osteoclast lineage commitment.
Chen W; Zhu G; Hao L; Wu M; Ci H; Li YP
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7294-9. PubMed ID: 23580622
[TBL] [Abstract][Full Text] [Related]
40. 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy.
Fenton CG; Doig CL; Fareed S; Naylor A; Morrell AP; Addison O; Wehmeyer C; Buckley CD; Cooper MS; Lavery GG; Raza K; Hardy RS
Arthritis Res Ther; 2019 Aug; 21(1):188. PubMed ID: 31420008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
